These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 5083866

  • 1. Central monoamine metabolism in Parkinson's disease.
    Chase TN, Ng LK.
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract] [Full Text] [Related]

  • 2. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK, Sonninen V, Siirtola T.
    Eur Neurol; 1973 Dec; 9(6):349-62. PubMed ID: 4712542
    [No Abstract] [Full Text] [Related]

  • 3. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B, Roos BE.
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract] [Full Text] [Related]

  • 4. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J, Sharpe D, Curzon G.
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract] [Full Text] [Related]

  • 5. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP, Korf J, Van Praag HM, Schut T.
    Nat New Biol; 1972 Apr 19; 236(68):208-9. PubMed ID: 4553111
    [No Abstract] [Full Text] [Related]

  • 6. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN, Watanabe AM.
    Neurology; 1972 Apr 19; 22(4):384-92. PubMed ID: 5062828
    [No Abstract] [Full Text] [Related]

  • 7. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C, Agnoli A, Jori A, Dolfini E.
    Z Neurol; 1973 Apr 02; 204(2):149-54. PubMed ID: 4121468
    [No Abstract] [Full Text] [Related]

  • 8. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH, Bowers MB.
    Experientia; 1970 Apr 02; 26(2):161-3. PubMed ID: 5308739
    [No Abstract] [Full Text] [Related]

  • 9. Parkinson's disease. Modification by 5-hydroxytryptophan.
    Chase TN, Ng LK, Watanabe AM.
    Neurology; 1972 May 02; 22(5):479-84. PubMed ID: 4563493
    [No Abstract] [Full Text] [Related]

  • 10. Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid.
    Chase RN, Schnur JA, Brody JA, Gordon EK.
    Arch Neurol; 1971 Jul 02; 25(1):9-13. PubMed ID: 5146413
    [No Abstract] [Full Text] [Related]

  • 11. Monoamine metabolism and depression in Parkinson patients.
    Puite JK, Schut T, van Praag HM, Lakke JP.
    Psychiatr Neurol Neurochir; 1973 Jul 02; 76(1):61-70. PubMed ID: 4699106
    [No Abstract] [Full Text] [Related]

  • 12. Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-dopa.
    Mendell JR, Chase TN, Engel WK.
    Trans Am Neurol Assoc; 1971 Jul 02; 96():284-6. PubMed ID: 5159109
    [No Abstract] [Full Text] [Related]

  • 13. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH, Bowers MB.
    Neurology; 1970 Apr 02; 20(4):377. PubMed ID: 5534981
    [No Abstract] [Full Text] [Related]

  • 14. Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism.
    Mendlewicz J, Vanderheyden JE, Noel G.
    Adv Exp Med Biol; 1981 Apr 02; 133():753-67. PubMed ID: 6172024
    [Abstract] [Full Text] [Related]

  • 15. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.
    Rinne UK, Sonninen V.
    Neurology; 1972 Jan 02; 22(1):62-7. PubMed ID: 4550499
    [No Abstract] [Full Text] [Related]

  • 16. The probenecid test in Parkinson's disease.
    Lakke JP, Korf J, Hoorntje S, Schut T, van Praag HM.
    Psychiatr Neurol Neurochir; 1973 Jan 02; 76(2):139-46. PubMed ID: 4700931
    [No Abstract] [Full Text] [Related]

  • 17. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA, Dowson JH, Ahmed R, Chow R, Gillingham FJ.
    Confin Neurol; 1972 Jan 02; 34(1):143-8. PubMed ID: 5084388
    [No Abstract] [Full Text] [Related]

  • 18. [Central metabolism of dopamine and serotonin. III. Preliminary findings on the relations between dopamine metabolism and purine metabolism in the nervous system].
    Campanella G, Orefice G, Carrieri P, Mandarini A, Buscaino GA.
    Acta Neurol (Napoli); 1976 Jan 02; 31(5):571-9. PubMed ID: 138341
    [No Abstract] [Full Text] [Related]

  • 19. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W, Danielczyk W, Neumayer E, Riederer P.
    J Neural Transm; 1972 Jan 02; 33(2):163-78. PubMed ID: 4643007
    [No Abstract] [Full Text] [Related]

  • 20. [Central metabolism of dopamine and serotonin. II. Significance of cerebrospinal fluid HVA and 5-HIAA changes in extrapyramidal and cerebellar syndromes].
    Buscaino GA, Mandarini A, Campanella G, Carrieri P, Orefice G.
    Acta Neurol (Napoli); 1976 Jan 02; 31(5):565-70. PubMed ID: 138340
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.